General
Preferred name
Lanifibranor
Synonyms
IVA337 ()
IVA-337 ()
Lanifibranor (IVA-337) ()
P&D ID
PD078464
CAS
927961-18-0
Tags
available
drug candidate
Drug indication
Non-alcoholic steatohepatitis
diffuse scleroderma
Drug Status
investigational
Max Phase
3.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Lanifibranor (IVA337) is a pan-peroxisome proliferator-activated receptor (PPAR) agonist that was developed as an antifibrotic clinical lead . (GtoPdb)
DESCRIPTION Lanifibranor is a pan peroxisome proliferator-activated receptor (PPAR) agonist with EC50 values of 1.5, 0.87 and 0.21 μM for human PPARα, PPARσ and PPARγ, respectively. (TargetMol Bioactive Compound Library)
Compound Sets
10
Cayman Chemical Bioactives
25572
ChEMBL Drugs
CHEMBL4091374
Drug Repurposing Hub
DrugBank
DB14801
DrugMAP
DMJV3AX
EUbOPEN Chemogenomics Library
EUB0001149
Guide to Pharmacology
12737
ReFrame library
Selleckchem Bioactive Compound Library
lanifibranor-iva-337
TargetMol Bioactive Compound Library
T7395
External IDs
17
Properties
(calculated by RDKit )
Molecular Weight
434.02
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
1
Rotatable Bonds
6
Ring Count
4
Aromatic Ring Count
4
cLogP
4.55
TPSA
89.26
Fraction CSP3
0.16
Chiral centers
0.0
Largest ring
6.0
QED
0.48
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
PPAR
MOA
PPAR receptor agonist
Pathway
DNA Damage/DNA Repair
Metabolism
Recommended Cell Concentration
1 uM
Source data